Synchron: The Less Invasive Path to Brain-Computer Interfaces
While Neuralink pursues a direct cortical implant approach, Synchron Inc. has developed a fundamentally different strategy for brain-computer interfacing — one that leverages the body’s existing vasculature to position electrodes near the brain without open neurosurgery. The Stentrode (stent-electrode recording array) is delivered through the jugular vein and deployed in the superior sagittal sinus, a major blood vessel that runs along the top of the brain near the motor cortex.
This endovascular approach offers significant advantages in safety, scalability, and accessibility, though it trades signal resolution for reduced invasiveness. Understanding the technical trade-offs between Synchron’s approach and Neuralink’s direct cortical implant is essential for assessing the competitive dynamics of the $2.94 billion BCI market.
The Stentrode System
The Stentrode consists of a self-expanding stent-like scaffold with integrated recording electrodes. The device is approximately 8mm in diameter when expanded and contains 16 electrodes positioned on the stent struts. The delivery procedure uses standard endovascular techniques familiar to interventional neuroradiologists — a catheter is inserted through the jugular vein, navigated to the superior sagittal sinus, and the Stentrode is deployed at the target location.
Over time, the Stentrode endothelializes — becoming incorporated into the vessel wall — creating a stable, chronic recording interface. The electrodes record electrocorticographic (ECoG) signals from the motor cortex through the vessel wall, capturing neural activity at a spatial resolution intermediate between scalp EEG (low resolution) and intracortical arrays (high resolution).
The recorded signals are transmitted wirelessly to an internal telemetry unit implanted in the chest, which in turn communicates with external processing devices. AI-based neural decoding algorithms — including NVIDIA AI integration — translate the decoded neural signals into digital control commands.
Clinical Progress
Synchron has conducted clinical trials in both Australia and the United States:
Australian Trials: The initial feasibility studies in Australia demonstrated that patients with severe paralysis could use the Stentrode to control digital devices, send text messages, and make online purchases using thought-based control. These trials established the safety of the endovascular delivery procedure and the long-term stability of the device.
US COMMAND Trial: The US-based COMMAND trial, conducted under FDA IDE approval, is evaluating the Stentrode in patients with ALS (amyotrophic lateral sclerosis). Early results have demonstrated successful device implantation, stable neural recordings, and meaningful functional capabilities.
NVIDIA AI and Apple Vision Pro Integration
In a significant technological advancement, Synchron integrated NVIDIA AI processing and Apple Vision Pro into its Stentrode ecosystem. This integration allows patients with severe paralysis to control digital and physical environments using neural signals processed by NVIDIA’s AI inference engines and displayed through Apple’s spatial computing platform.
The integration demonstrates the convergence of brain-computer interfaces, deep learning, and consumer technology platforms — a convergence that could accelerate BCI adoption by leveraging existing hardware and software ecosystems rather than requiring entirely custom solutions.
The Chiral Cognitive AI Roadmap
In March 2025, Synchron announced the roadmap for “Chiral,” a foundation model of human cognition trained directly on neural activity recorded through BCI devices. This is perhaps the most ambitious project in the intersection of neural networks and brain-computer interfaces, and it has profound implications for consciousness research.
Chiral aims to create an AI system whose internal representations are directly grounded in human neural activity — not derived from text, images, or other behavioral data, but from the actual patterns of brain activity that accompany human thought, perception, and action. If successful, Chiral would represent:
A New Class of Foundation Model: Unlike transformers trained on text or images, Chiral would be trained on neural data, creating representations that capture aspects of human cognition inaccessible to other training modalities.
A Bridge to Consciousness Research: A model trained on neural activity from consciousness-associated brain regions could provide insights into how neural dynamics give rise to conscious experience — directly relevant to the consciousness indicators framework and theories like Global Workspace Theory and Integrated Information Theory.
Enhanced BCI Decoding: A foundation model of cognition could dramatically improve neural signal decoding by providing a prior over the space of possible cognitive states, analogous to how language models improve speech recognition by providing linguistic priors.
Comparison with Neuralink
The fundamental trade-off between Synchron and Neuralink is signal quality versus invasiveness:
Neuralink Advantages: 1,024 electrodes vs. Synchron’s 16. Direct cortical recording provides single-neuron resolution. Higher bandwidth enables more sophisticated decoding tasks including speech restoration.
Synchron Advantages: No open neurosurgery required — the procedure uses standard endovascular techniques with lower risk of complications. Faster recovery time. More scalable to larger patient populations because the implantation procedure can be performed by interventional neuroradiologists rather than neurosurgeons.
Signal Quality: Neuralink records from within the cortex, capturing individual neuron firing patterns. Synchron records through the vessel wall, capturing aggregate activity from populations of neurons. This difference in signal resolution affects the complexity of decoding tasks that each system can support.
For detailed side-by-side analysis, see our Neuralink vs. Synchron vs. Blackrock comparison.
Market Position
Synchron has raised significant venture capital and attracted attention from major technology companies. Its partnership with NVIDIA and Apple positions it at the intersection of neurotechnology, AI, and consumer technology — a convergence that could prove more commercially significant than pure neurotechnology approaches.
The company’s focus on ALS patients — a population with urgent, unmet needs for communication and environmental control — provides a clear clinical pathway and regulatory narrative. ALS patients represent an initial market that could generate revenue while the technology is refined for broader applications.
For ongoing coverage of Synchron and the broader BCI market, see our Brain-Computer Interfaces vertical, entity profiles, and market dashboards.
Endovascular BCI: The Technical Deep-Dive
The endovascular approach to brain-computer interfacing exploits the anatomical relationship between the cerebral vasculature and the brain’s cortical surface. The superior sagittal sinus — the blood vessel in which the Stentrode is deployed — runs along the midline of the brain directly above the motor cortex, placing the electrodes within millimeters of the neural populations that encode movement intentions.
Electrocorticographic Recording: The Stentrode records electrocorticographic (ECoG) signals rather than single-neuron spikes. ECoG captures the aggregate electrical activity of neural populations, producing signals with spectral characteristics (power in specific frequency bands, event-related spectral perturbations) that correlate with motor intentions. While ECoG provides less spatial resolution than intracortical recording, it offers superior long-term stability because the electrodes do not penetrate brain tissue and are not subject to the gliosis and electrode degradation that affect penetrating arrays.
Signal Processing Pipeline: The recorded ECoG signals undergo preprocessing to remove vascular and cardiac artifacts, followed by feature extraction in multiple frequency bands (theta, alpha, beta, low gamma, high gamma). High-gamma activity (70-200 Hz) is particularly informative for motor decoding, as it reflects local cortical processing with reasonable spatial specificity. Deep learning models trained on these spectral features classify motor intentions and generate control commands for digital devices.
Chronic Stability: One of the Stentrode’s most significant advantages is its demonstrated chronic stability. Because the device becomes endothelialized — incorporated into the vessel wall — it achieves biological fixation without mechanical anchoring. Australian clinical data has demonstrated stable neural recordings over multiple years of implantation, suggesting that the endovascular approach may offer superior long-term reliability compared to penetrating arrays that are subject to ongoing tissue reactions.
Patient Selection and Clinical Pathway
The Stentrode is primarily targeted at patients with ALS (amyotrophic lateral sclerosis), a progressive neurodegenerative disease that destroys motor neurons while leaving cognitive function intact. ALS patients represent an ideal initial population for several reasons:
Progressive Loss: ALS patients experience progressive loss of motor function, eventually losing the ability to speak, move, and breathe independently. BCI technology offers the possibility of maintaining communication and digital interaction capability as the disease progresses, significantly improving quality of life during the later stages.
Preserved Cognition: Unlike some neurological conditions, ALS preserves cognitive function. Patients can learn to use BCI systems effectively because their ability to generate motor intentions in the cortex remains intact even after the motor pathways to muscles are destroyed.
Urgent Unmet Need: There is no cure for ALS, and existing assistive technologies (eye tracking, switch scanning) become increasingly inadequate as the disease progresses. The clinical urgency of the patient population supports regulatory arguments for accelerated pathways and compassionate use.
Comparison with Other Endovascular Neural Interfaces
While Synchron is the most advanced company pursuing the endovascular BCI approach, the concept has attracted attention from other researchers and companies. The endovascular route to the brain has been used clinically for decades in stroke treatment (thrombectomy), aneurysm repair (coiling), and vascular malformation treatment (embolization), establishing the safety and feasibility of navigating catheters to brain vasculature.
Several academic groups have explored endovascular neural recording and stimulation, including researchers at the University of Melbourne (where the Stentrode was developed), Massachusetts General Hospital, and various European institutions. These research programs are exploring different electrode designs, vascular targets, and recording strategies that could complement or compete with Synchron’s approach.
Intellectual Property and Trade Secrets
Synchron has built a patent portfolio covering the Stentrode device design, endovascular delivery techniques, signal processing algorithms, and the integration of neural recording with AI processing and consumer technology platforms. The company’s IP position is strengthened by trade secrets related to manufacturing processes, electrode optimization, and the proprietary algorithms used in the NVIDIA AI integration.
Market Positioning and Revenue Strategy
Synchron’s path to revenue involves several stages: regulatory approval in multiple jurisdictions, reimbursement establishment with insurance payers, manufacturing scale-up, and clinical adoption by the interventional neuroradiology community. The company’s strategy of partnering with major technology companies (NVIDIA, Apple) positions it to leverage existing distribution channels and technology ecosystems rather than building everything from scratch.
The global BCI market is projected to reach $13.86 billion by 2035. Within this market, the endovascular BCI segment could capture significant share if the Stentrode achieves regulatory approval and demonstrates adequate clinical performance. The endovascular approach’s scalability advantage — the procedure can be performed by a larger pool of clinicians with less specialized surgical infrastructure — could enable faster market penetration than more invasive approaches.
The Endovascular BCI: Future Applications
Beyond ALS and paralysis, the endovascular approach opens potential applications that are impractical for invasive intracortical devices. The relative simplicity and safety of the implantation procedure could enable BCI technology to serve broader patient populations with conditions such as treatment-resistant depression (recording from prefrontal regions for mood-responsive neuromodulation), epilepsy (detecting seizure onset patterns through vascular proximity to cortical foci), and chronic pain (decoding pain-related neural signatures for closed-loop pain management). The endovascular approach also raises intriguing possibilities for research applications. Researchers studying consciousness could use Stentrode recordings to study the neural dynamics of the global workspace through a chronically implanted, minimally invasive device — providing longitudinal data on consciousness-related neural activity that is currently impossible to obtain with non-invasive methods. The cognitive computing field could benefit from chronic neural recordings that track cognitive state changes over weeks and months, providing training data for more sophisticated AI models of human cognition — ultimately feeding into the Chiral foundation model project that represents Synchron’s most ambitious long-term vision.
For ongoing coverage of Synchron and the broader BCI market, see our Brain-Computer Interfaces vertical, entity profiles, and market dashboards.
Synchron’s Competitive Moat and Strategic Outlook
Synchron’s competitive position rests on several reinforcing advantages that distinguish it within the $2.94 billion BCI market. The endovascular delivery technique leverages decades of interventional neuroradiology infrastructure — catheter labs, trained physicians, established reimbursement codes for endovascular procedures — that dramatically reduce the go-to-market friction compared to novel surgical approaches. The NVIDIA AI and Apple Vision Pro partnerships embed Synchron within the world’s most valuable consumer and enterprise technology ecosystems, creating distribution advantages that pure medical device companies cannot replicate. The Chiral cognitive AI roadmap positions Synchron at the intersection of the $390.9 billion AI market and the neurotechnology industry, creating optionality beyond hardware revenue. And the company’s growing patent portfolio covering endovascular neural recording, stimulation techniques, and AI-mediated signal processing builds a durable intellectual property moat. As the BCI market approaches its projected $13.86 billion valuation by 2035, Synchron’s combination of clinical progress, technology partnerships, and ambitious research vision positions it as one of the most strategically significant companies in the brain-computer interface industry.
Updated March 2026. Contact info@subconsciousmind.ai for corrections.